Baili Tianheng Announcement: The company recently received the official approval notice for drug clinical trial issued by the National Medical Products Administration (NMPA). The drug clinical trial of the company's independently developed innovative biopharmaceutical multi-specific antibody GNC-077 has been approved. GNC-077 is an innovative multi-specific antibody molecule independently developed by the company relying on the global leading innovative multi-specific antibody drug development platform, which includes antibody domains targeting T cell CD3 and T cell immune checkpoints, as well as antibody domains targeting tumor antigens. GNC-077 can effectively induce the activation, differentiation, and proliferation of T cells, and mediate the targeted killing of tumor antigen-positive tumor cells by activated T cells. According to the relevant laws and regulations of drug registration in China, after obtaining the approval notice for drug clinical trials, clinical trials are still required to be carried out and approved by the NMPA before production and marketing can be implemented.